Michael Graner
Concepts (405)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Extracellular Vesicles | 7 | 2022 | 82 | 3.240 |
Why?
| Exosomes | 11 | 2020 | 92 | 2.950 |
Why?
| Glioma | 10 | 2019 | 296 | 2.870 |
Why?
| Cancer Vaccines | 15 | 2018 | 137 | 2.160 |
Why?
| Molecular Chaperones | 16 | 2013 | 157 | 2.070 |
Why?
| Brain Neoplasms | 12 | 2022 | 979 | 2.070 |
Why?
| Neoplasms | 10 | 2021 | 2114 | 1.570 |
Why?
| Multiple Sclerosis | 8 | 2023 | 380 | 1.440 |
Why?
| Tumor Microenvironment | 3 | 2019 | 424 | 1.170 |
Why?
| Antigens, Neoplasm | 7 | 2018 | 224 | 1.130 |
Why?
| Cytokines | 5 | 2021 | 1858 | 1.130 |
Why?
| Glioblastoma | 4 | 2022 | 251 | 1.110 |
Why?
| Immunoglobulin G | 7 | 2023 | 782 | 1.040 |
Why?
| Unfolded Protein Response | 3 | 2016 | 45 | 1.030 |
Why?
| HSP90 Heat-Shock Proteins | 4 | 2015 | 43 | 1.010 |
Why?
| Immune Tolerance | 2 | 2018 | 331 | 0.980 |
Why?
| Oligoclonal Bands | 4 | 2022 | 21 | 0.950 |
Why?
| HSP70 Heat-Shock Proteins | 6 | 2015 | 61 | 0.940 |
Why?
| Stroke | 2 | 2023 | 1016 | 0.900 |
Why?
| Proteome | 5 | 2014 | 346 | 0.890 |
Why?
| Gene Expression Regulation, Neoplastic | 6 | 2019 | 1143 | 0.870 |
Why?
| Heat-Shock Proteins | 6 | 2013 | 113 | 0.850 |
Why?
| Ischemic Attack, Transient | 1 | 2023 | 61 | 0.820 |
Why?
| Antineoplastic Agents | 7 | 2021 | 1891 | 0.770 |
Why?
| Meningioma | 1 | 2022 | 78 | 0.750 |
Why?
| Extracellular Space | 4 | 2015 | 121 | 0.750 |
Why?
| Meningeal Neoplasms | 1 | 2022 | 88 | 0.750 |
Why?
| Immunity | 3 | 2018 | 125 | 0.700 |
Why?
| Astrocytes | 2 | 2019 | 165 | 0.680 |
Why?
| Brain Ischemia | 1 | 2023 | 298 | 0.670 |
Why?
| Vacuolar Proton-Translocating ATPases | 1 | 2019 | 13 | 0.660 |
Why?
| Antigen Presentation | 4 | 2018 | 189 | 0.660 |
Why?
| Immunomodulation | 2 | 2018 | 86 | 0.640 |
Why?
| Proteomics | 5 | 2020 | 855 | 0.640 |
Why?
| Neoplasm Proteins | 2 | 2016 | 388 | 0.640 |
Why?
| Cell Line, Tumor | 17 | 2018 | 2749 | 0.620 |
Why?
| RNA, Neoplasm | 1 | 2018 | 80 | 0.620 |
Why?
| MicroRNAs | 3 | 2018 | 610 | 0.590 |
Why?
| T-Lymphocytes | 4 | 2018 | 1758 | 0.580 |
Why?
| Brain Injuries | 1 | 2021 | 451 | 0.550 |
Why?
| Signal Transduction | 8 | 2020 | 4527 | 0.510 |
Why?
| Cell Proliferation | 7 | 2018 | 2196 | 0.490 |
Why?
| Calreticulin | 2 | 2013 | 23 | 0.490 |
Why?
| Animals | 40 | 2023 | 32158 | 0.490 |
Why?
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2013 | 19 | 0.450 |
Why?
| Humans | 55 | 2023 | 115859 | 0.440 |
Why?
| Dog Diseases | 1 | 2013 | 41 | 0.430 |
Why?
| Leukocytes, Mononuclear | 1 | 2015 | 503 | 0.420 |
Why?
| Heat-Shock Response | 2 | 2015 | 46 | 0.420 |
Why?
| Mice, Inbred BALB C | 13 | 2014 | 1169 | 0.420 |
Why?
| Autoantibodies | 1 | 2020 | 1362 | 0.410 |
Why?
| Cerebellar Neoplasms | 1 | 2012 | 131 | 0.370 |
Why?
| Medulloblastoma | 1 | 2012 | 172 | 0.360 |
Why?
| Stress, Physiological | 1 | 2013 | 399 | 0.360 |
Why?
| Mice | 24 | 2023 | 15085 | 0.360 |
Why?
| Transcription Factors | 2 | 2014 | 1535 | 0.340 |
Why?
| Drug Resistance, Neoplasm | 2 | 2013 | 638 | 0.340 |
Why?
| Mycobacterium tuberculosis | 7 | 2015 | 271 | 0.330 |
Why?
| Tuberculosis | 4 | 2015 | 244 | 0.320 |
Why?
| Dendritic Cells | 11 | 2008 | 438 | 0.310 |
Why?
| Carrier Proteins | 2 | 2009 | 703 | 0.290 |
Why?
| Interleukin-6 | 4 | 2023 | 677 | 0.280 |
Why?
| Histocompatibility Antigens Class I | 3 | 2018 | 173 | 0.270 |
Why?
| Isoelectric Focusing | 3 | 2015 | 34 | 0.270 |
Why?
| Neoplasms, Experimental | 3 | 2006 | 153 | 0.270 |
Why?
| Immunotherapy | 3 | 2021 | 481 | 0.270 |
Why?
| Lymphocyte Activation | 4 | 2012 | 1056 | 0.260 |
Why?
| Case-Control Studies | 5 | 2021 | 3054 | 0.260 |
Why?
| Interferon-gamma | 8 | 2015 | 733 | 0.260 |
Why?
| Cell Movement | 6 | 2018 | 867 | 0.250 |
Why?
| Peptides | 4 | 2022 | 864 | 0.250 |
Why?
| Oligopeptides | 4 | 2007 | 248 | 0.250 |
Why?
| Amino Acid Sequence | 6 | 2020 | 2003 | 0.240 |
Why?
| Albumins | 1 | 2004 | 91 | 0.240 |
Why?
| Female | 28 | 2023 | 60070 | 0.230 |
Why?
| Fusion Proteins, bcr-abl | 4 | 2007 | 61 | 0.230 |
Why?
| Integrins | 3 | 1998 | 79 | 0.230 |
Why?
| Leukemia, B-Cell | 2 | 2000 | 11 | 0.220 |
Why?
| Multiple Sclerosis, Chronic Progressive | 1 | 2023 | 25 | 0.220 |
Why?
| Neuroblastoma | 2 | 2023 | 130 | 0.220 |
Why?
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2023 | 69 | 0.210 |
Why?
| Membrane Glycoproteins | 4 | 2015 | 433 | 0.210 |
Why?
| Drosophila Proteins | 3 | 1998 | 159 | 0.210 |
Why?
| Lung Neoplasms | 2 | 2013 | 2206 | 0.210 |
Why?
| Transferases | 1 | 2022 | 28 | 0.200 |
Why?
| Tuberculosis, Pleural | 2 | 2014 | 6 | 0.200 |
Why?
| Tuberculosis, Pulmonary | 3 | 2012 | 112 | 0.200 |
Why?
| Organ Specificity | 2 | 2020 | 274 | 0.200 |
Why?
| Middle Aged | 13 | 2023 | 27078 | 0.190 |
Why?
| Xenograft Model Antitumor Assays | 4 | 2013 | 703 | 0.190 |
Why?
| Apoptosis | 3 | 2023 | 2377 | 0.190 |
Why?
| Epitopes | 2 | 2020 | 438 | 0.190 |
Why?
| Peptide Fragments | 4 | 2020 | 675 | 0.190 |
Why?
| Blotting, Western | 4 | 2009 | 1153 | 0.190 |
Why?
| Tissue Plasminogen Activator | 1 | 2023 | 228 | 0.180 |
Why?
| Cell Extracts | 3 | 2006 | 15 | 0.180 |
Why?
| Laser Capture Microdissection | 1 | 2020 | 23 | 0.180 |
Why?
| Ultracentrifugation | 1 | 2020 | 48 | 0.180 |
Why?
| Extracellular Matrix Proteins | 2 | 1998 | 128 | 0.180 |
Why?
| Immunosuppressive Agents | 1 | 2004 | 666 | 0.180 |
Why?
| CD4-Positive T-Lymphocytes | 3 | 2012 | 967 | 0.180 |
Why?
| Plasma Cells | 1 | 2020 | 57 | 0.180 |
Why?
| Prognosis | 2 | 2021 | 3344 | 0.180 |
Why?
| Male | 18 | 2023 | 56103 | 0.180 |
Why?
| Antibody Specificity | 1 | 2020 | 180 | 0.170 |
Why?
| Peptide Library | 1 | 2020 | 81 | 0.170 |
Why?
| Protein Transport | 2 | 2019 | 400 | 0.170 |
Why?
| Epstein-Barr Virus Infections | 1 | 2020 | 71 | 0.170 |
Why?
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2007 | 93 | 0.170 |
Why?
| Virus Latency | 1 | 2020 | 80 | 0.170 |
Why?
| Nanoparticles | 2 | 2020 | 316 | 0.170 |
Why?
| Cells, Cultured | 6 | 2015 | 3914 | 0.170 |
Why?
| Tumor Cells, Cultured | 6 | 2007 | 850 | 0.160 |
Why?
| Bacteriophages | 1 | 2020 | 76 | 0.160 |
Why?
| Lymphoma, B-Cell | 1 | 2000 | 85 | 0.160 |
Why?
| Transcription, Genetic | 3 | 2014 | 1317 | 0.160 |
Why?
| Receptors, Purinergic | 1 | 2018 | 20 | 0.160 |
Why?
| Tenascin | 1 | 1998 | 13 | 0.160 |
Why?
| Receptors, Fc | 1 | 2018 | 45 | 0.160 |
Why?
| Laminin | 1 | 1998 | 69 | 0.160 |
Why?
| Ovarian Neoplasms | 2 | 2017 | 407 | 0.160 |
Why?
| Alternative Splicing | 2 | 2006 | 187 | 0.160 |
Why?
| Antigen-Presenting Cells | 1 | 2018 | 152 | 0.150 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2017 | 935 | 0.150 |
Why?
| Leukemia | 3 | 2006 | 207 | 0.150 |
Why?
| DNA, Viral | 1 | 2020 | 351 | 0.150 |
Why?
| Milk | 1 | 2018 | 124 | 0.150 |
Why?
| Drug Carriers | 1 | 2018 | 113 | 0.150 |
Why?
| Immune System | 1 | 2019 | 173 | 0.150 |
Why?
| DNA Methylation | 1 | 2022 | 502 | 0.150 |
Why?
| Prostatic Neoplasms | 2 | 2015 | 927 | 0.150 |
Why?
| Cell Hypoxia | 2 | 2015 | 220 | 0.150 |
Why?
| Biological Transport | 1 | 2018 | 375 | 0.150 |
Why?
| Host-Pathogen Interactions | 1 | 2020 | 296 | 0.140 |
Why?
| Autoantigens | 1 | 2020 | 399 | 0.140 |
Why?
| Antigens, Bacterial | 2 | 2015 | 112 | 0.140 |
Why?
| Inflammation | 2 | 2019 | 2502 | 0.140 |
Why?
| Adenosine Triphosphate | 1 | 2018 | 430 | 0.130 |
Why?
| Herpesvirus 3, Human | 1 | 2020 | 381 | 0.130 |
Why?
| Mass Spectrometry | 2 | 2016 | 643 | 0.130 |
Why?
| Lymphocytes | 1 | 2017 | 342 | 0.130 |
Why?
| Brain | 3 | 2020 | 2372 | 0.130 |
Why?
| Neurons | 2 | 2022 | 1298 | 0.130 |
Why?
| Protein Array Analysis | 1 | 2015 | 61 | 0.130 |
Why?
| Antigens, Surface | 1 | 2015 | 151 | 0.130 |
Why?
| DNA | 1 | 2022 | 1357 | 0.130 |
Why?
| Sequence Analysis, RNA | 1 | 2017 | 390 | 0.120 |
Why?
| Aged | 6 | 2023 | 19292 | 0.120 |
Why?
| RNA, Messenger | 5 | 2020 | 2581 | 0.120 |
Why?
| Granuloma | 1 | 2015 | 85 | 0.120 |
Why?
| Lung | 3 | 2017 | 3683 | 0.120 |
Why?
| Alkynes | 1 | 2014 | 54 | 0.120 |
Why?
| Azides | 1 | 2014 | 47 | 0.120 |
Why?
| Click Chemistry | 1 | 2014 | 50 | 0.120 |
Why?
| BCG Vaccine | 2 | 2010 | 18 | 0.120 |
Why?
| Flow Cytometry | 3 | 2012 | 1060 | 0.120 |
Why?
| Acute Lung Injury | 1 | 2017 | 302 | 0.120 |
Why?
| Adherens Junctions | 1 | 2013 | 26 | 0.110 |
Why?
| Intestinal Mucosa | 1 | 2018 | 528 | 0.110 |
Why?
| Interferon-gamma Release Tests | 1 | 2014 | 26 | 0.110 |
Why?
| Pleural Effusion | 1 | 2014 | 46 | 0.110 |
Why?
| Mice, Inbred C57BL | 6 | 2017 | 4779 | 0.110 |
Why?
| Basigin | 1 | 2013 | 25 | 0.110 |
Why?
| Triglycerides | 1 | 2015 | 471 | 0.110 |
Why?
| Antineoplastic Agents, Alkylating | 1 | 2013 | 68 | 0.110 |
Why?
| Adult | 12 | 2023 | 30814 | 0.110 |
Why?
| Dacarbazine | 1 | 2013 | 100 | 0.110 |
Why?
| Histocompatibility Antigens Class II | 2 | 2013 | 352 | 0.110 |
Why?
| Lipogenesis | 1 | 2013 | 57 | 0.110 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2013 | 118 | 0.110 |
Why?
| Endoplasmic Reticulum Stress | 1 | 2013 | 92 | 0.110 |
Why?
| Aged, 80 and over | 2 | 2023 | 6434 | 0.110 |
Why?
| Drosophila | 3 | 1998 | 132 | 0.110 |
Why?
| ErbB Receptors | 2 | 2006 | 557 | 0.110 |
Why?
| T-Lymphocytes, Cytotoxic | 6 | 2015 | 156 | 0.110 |
Why?
| Hepatocyte Nuclear Factor 4 | 1 | 2012 | 13 | 0.110 |
Why?
| Neoplasm Grading | 1 | 2013 | 244 | 0.110 |
Why?
| Prostate | 1 | 2013 | 157 | 0.110 |
Why?
| Liver | 2 | 2013 | 1693 | 0.100 |
Why?
| Treatment Outcome | 3 | 2023 | 9163 | 0.100 |
Why?
| Transforming Growth Factor beta1 | 1 | 2013 | 156 | 0.100 |
Why?
| Tumor Burden | 1 | 2013 | 261 | 0.100 |
Why?
| Dogs | 1 | 2013 | 344 | 0.100 |
Why?
| B-Lymphocytes | 2 | 2022 | 771 | 0.100 |
Why?
| Neutrophils | 1 | 2017 | 1171 | 0.100 |
Why?
| Gene Regulatory Networks | 1 | 2013 | 234 | 0.100 |
Why?
| Epithelial Cells | 1 | 2017 | 961 | 0.100 |
Why?
| Th17 Cells | 1 | 2012 | 58 | 0.100 |
Why?
| Phenotype | 3 | 2018 | 2859 | 0.100 |
Why?
| B-Lymphocyte Subsets | 1 | 2012 | 67 | 0.100 |
Why?
| Cell Line | 4 | 2020 | 2657 | 0.100 |
Why?
| RNA-Binding Proteins | 1 | 2014 | 363 | 0.100 |
Why?
| Mice, Nude | 3 | 2007 | 639 | 0.100 |
Why?
| Cell Survival | 2 | 2012 | 1024 | 0.090 |
Why?
| Oxygen | 1 | 2015 | 837 | 0.090 |
Why?
| Enzyme-Linked Immunospot Assay | 1 | 2010 | 34 | 0.090 |
Why?
| Interleukin-17 | 1 | 2011 | 106 | 0.090 |
Why?
| Radiography | 1 | 2013 | 826 | 0.090 |
Why?
| Transforming Growth Factor beta | 3 | 2011 | 447 | 0.090 |
Why?
| Immunity, Innate | 1 | 2015 | 735 | 0.090 |
Why?
| Receptors, Interleukin-6 | 1 | 2009 | 35 | 0.090 |
Why?
| Latent Tuberculosis | 1 | 2010 | 64 | 0.090 |
Why?
| Immunohistochemistry | 3 | 2009 | 1644 | 0.090 |
Why?
| Tissue Array Analysis | 1 | 2009 | 49 | 0.080 |
Why?
| Interleukins | 1 | 2011 | 237 | 0.080 |
Why?
| Mycobacterium bovis | 1 | 2009 | 11 | 0.080 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 2 | 2008 | 104 | 0.080 |
Why?
| T-Lymphocytes, Helper-Inducer | 1 | 2009 | 129 | 0.080 |
Why?
| Cross-Priming | 1 | 2008 | 19 | 0.080 |
Why?
| Enzyme-Linked Immunosorbent Assay | 3 | 2023 | 796 | 0.080 |
Why?
| Electrophoresis, Gel, Two-Dimensional | 1 | 2008 | 100 | 0.080 |
Why?
| Adaptor Proteins, Signal Transducing | 2 | 2009 | 377 | 0.080 |
Why?
| Antigens, Differentiation | 1 | 2008 | 79 | 0.080 |
Why?
| Toll-Like Receptor 2 | 1 | 2009 | 114 | 0.080 |
Why?
| Carcinoma, Lewis Lung | 2 | 2005 | 13 | 0.080 |
Why?
| Blood-Brain Barrier | 1 | 2008 | 106 | 0.080 |
Why?
| Neoplasm Transplantation | 3 | 2006 | 235 | 0.080 |
Why?
| DNA-Binding Proteins | 1 | 2014 | 1318 | 0.070 |
Why?
| Hypoxia | 1 | 2013 | 937 | 0.070 |
Why?
| Immunotherapy, Active | 1 | 2007 | 8 | 0.070 |
Why?
| Tissue Extracts | 1 | 2007 | 20 | 0.070 |
Why?
| Immunization | 3 | 2015 | 402 | 0.070 |
Why?
| Biomarkers | 4 | 2023 | 3474 | 0.070 |
Why?
| Angiogenesis Inhibitors | 1 | 2008 | 216 | 0.070 |
Why?
| Tissue Distribution | 2 | 2018 | 324 | 0.070 |
Why?
| Cell Membrane | 1 | 2009 | 683 | 0.060 |
Why?
| Vitamin E | 1 | 2005 | 111 | 0.060 |
Why?
| T-Lymphocyte Subsets | 1 | 2007 | 383 | 0.060 |
Why?
| Spleen | 2 | 2004 | 492 | 0.060 |
Why?
| Immunotherapy, Adoptive | 2 | 2004 | 194 | 0.060 |
Why?
| Integrin alpha Chains | 3 | 1998 | 22 | 0.060 |
Why?
| Piperidines | 1 | 2005 | 163 | 0.060 |
Why?
| Quinazolines | 1 | 2005 | 241 | 0.060 |
Why?
| Central Nervous System Neoplasms | 1 | 2005 | 125 | 0.060 |
Why?
| Disease Models, Animal | 1 | 2013 | 3587 | 0.060 |
Why?
| Molecular Sequence Data | 3 | 2015 | 2796 | 0.060 |
Why?
| Kinetics | 2 | 2006 | 1568 | 0.060 |
Why?
| Neoplasm Invasiveness | 2 | 2015 | 445 | 0.050 |
Why?
| Melanoma | 1 | 2008 | 649 | 0.050 |
Why?
| Head and Neck Neoplasms | 1 | 2006 | 425 | 0.050 |
Why?
| Piperazines | 1 | 2004 | 314 | 0.050 |
Why?
| Interleukin-12 | 3 | 2008 | 110 | 0.050 |
Why?
| Recombinant Proteins | 2 | 2020 | 1244 | 0.050 |
Why?
| Survival Analysis | 2 | 2006 | 1218 | 0.050 |
Why?
| Carcinoma, Squamous Cell | 1 | 2006 | 577 | 0.050 |
Why?
| Pyrimidines | 1 | 2004 | 376 | 0.050 |
Why?
| Cell Division | 1 | 2003 | 760 | 0.050 |
Why?
| Chromatography | 1 | 2000 | 24 | 0.050 |
Why?
| Lipids | 1 | 2004 | 589 | 0.050 |
Why?
| Epstein-Barr Virus Nuclear Antigens | 1 | 2020 | 8 | 0.050 |
Why?
| Chemical Precipitation | 1 | 2020 | 38 | 0.050 |
Why?
| Dose-Response Relationship, Drug | 2 | 2005 | 1871 | 0.050 |
Why?
| Vaccination | 1 | 2008 | 1209 | 0.050 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2006 | 524 | 0.050 |
Why?
| Injections, Spinal | 1 | 2020 | 102 | 0.040 |
Why?
| Electrophoresis, Polyacrylamide Gel | 1 | 2000 | 313 | 0.040 |
Why?
| bcl-X Protein | 1 | 2020 | 39 | 0.040 |
Why?
| Complement System Proteins | 1 | 2023 | 288 | 0.040 |
Why?
| Electron Transport Complex IV | 1 | 2020 | 53 | 0.040 |
Why?
| 3T3 Cells | 1 | 2000 | 137 | 0.040 |
Why?
| Immediate-Early Proteins | 1 | 2020 | 53 | 0.040 |
Why?
| Herpesvirus 4, Human | 1 | 2020 | 123 | 0.040 |
Why?
| Ligands | 2 | 1998 | 570 | 0.040 |
Why?
| Viral Envelope Proteins | 1 | 2020 | 74 | 0.040 |
Why?
| China | 2 | 2010 | 165 | 0.040 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2000 | 139 | 0.040 |
Why?
| Ribonucleoproteins | 1 | 2000 | 87 | 0.040 |
Why?
| Up-Regulation | 2 | 2013 | 824 | 0.040 |
Why?
| Young Adult | 5 | 2014 | 10508 | 0.040 |
Why?
| Caspase 3 | 1 | 2020 | 237 | 0.040 |
Why?
| Carbocyanines | 1 | 2018 | 30 | 0.040 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2020 | 213 | 0.040 |
Why?
| Biological Availability | 1 | 2018 | 119 | 0.040 |
Why?
| Calcium-Binding Proteins | 1 | 2000 | 206 | 0.040 |
Why?
| Protein Conformation | 2 | 1998 | 822 | 0.040 |
Why?
| Permeability | 1 | 2018 | 151 | 0.040 |
Why?
| Solubility | 1 | 2018 | 226 | 0.040 |
Why?
| RNA Transport | 1 | 2017 | 22 | 0.040 |
Why?
| Poly(ADP-ribose) Polymerases | 1 | 2017 | 88 | 0.040 |
Why?
| Sensitivity and Specificity | 2 | 2014 | 1725 | 0.040 |
Why?
| Antibodies, Viral | 1 | 2020 | 527 | 0.040 |
Why?
| Fluorescent Dyes | 1 | 2018 | 303 | 0.040 |
Why?
| Cell Adhesion | 1 | 1998 | 433 | 0.040 |
Why?
| Gene Knockdown Techniques | 1 | 2017 | 303 | 0.030 |
Why?
| Administration, Oral | 1 | 2018 | 733 | 0.030 |
Why?
| Gene Expression Regulation | 2 | 2020 | 2365 | 0.030 |
Why?
| Antibodies, Monoclonal | 3 | 2008 | 1264 | 0.030 |
Why?
| Cattle | 1 | 2018 | 935 | 0.030 |
Why?
| Cell Communication | 1 | 2017 | 280 | 0.030 |
Why?
| Fetus | 1 | 2020 | 703 | 0.030 |
Why?
| Drug Screening Assays, Antitumor | 2 | 2007 | 180 | 0.030 |
Why?
| Blood Proteins | 1 | 2017 | 238 | 0.030 |
Why?
| Lymphocyte Culture Test, Mixed | 2 | 2007 | 43 | 0.030 |
Why?
| Fibroblasts | 1 | 2020 | 838 | 0.030 |
Why?
| Muscle Contraction | 1 | 1998 | 398 | 0.030 |
Why?
| Protein Binding | 1 | 2000 | 1918 | 0.030 |
Why?
| Pharmaceutical Vehicles | 1 | 2014 | 11 | 0.030 |
Why?
| Cycloaddition Reaction | 1 | 2014 | 24 | 0.030 |
Why?
| Chemistry, Pharmaceutical | 1 | 2014 | 99 | 0.030 |
Why?
| Injections, Intravenous | 1 | 2014 | 204 | 0.030 |
Why?
| Fluorescence | 1 | 2015 | 153 | 0.030 |
Why?
| Antibiotics, Antineoplastic | 1 | 2014 | 114 | 0.030 |
Why?
| Annexin A2 | 1 | 2013 | 10 | 0.030 |
Why?
| Tetraspanins | 1 | 2013 | 15 | 0.030 |
Why?
| Phosphatidylcholines | 1 | 2014 | 134 | 0.030 |
Why?
| Choline | 1 | 2014 | 108 | 0.030 |
Why?
| Membrane Proteins | 1 | 2000 | 1033 | 0.030 |
Why?
| Copper | 1 | 2014 | 101 | 0.030 |
Why?
| Cross-Linking Reagents | 1 | 2014 | 182 | 0.030 |
Why?
| Metalloproteases | 1 | 2013 | 37 | 0.030 |
Why?
| Epitopes, T-Lymphocyte | 1 | 2015 | 171 | 0.030 |
Why?
| Liposomes | 1 | 2014 | 149 | 0.030 |
Why?
| Particle Size | 1 | 2014 | 320 | 0.030 |
Why?
| Doxorubicin | 1 | 2014 | 290 | 0.030 |
Why?
| Coculture Techniques | 1 | 2013 | 204 | 0.030 |
Why?
| Surface Properties | 1 | 2014 | 397 | 0.030 |
Why?
| Feedback, Physiological | 1 | 2013 | 74 | 0.030 |
Why?
| Infant, Newborn | 1 | 2023 | 5084 | 0.030 |
Why?
| CD5 Antigens | 1 | 2012 | 8 | 0.030 |
Why?
| Ionomycin | 1 | 2012 | 24 | 0.030 |
Why?
| Pneumonia | 1 | 2017 | 576 | 0.030 |
Why?
| Antigens, CD1d | 1 | 2012 | 63 | 0.030 |
Why?
| Drug Delivery Systems | 1 | 2014 | 301 | 0.020 |
Why?
| Tetradecanoylphorbol Acetate | 1 | 2012 | 153 | 0.020 |
Why?
| Lymphocyte Count | 1 | 2012 | 133 | 0.020 |
Why?
| Cell Aggregation | 1 | 2011 | 24 | 0.020 |
Why?
| Antigens, CD19 | 1 | 2012 | 97 | 0.020 |
Why?
| Th1 Cells | 1 | 2012 | 125 | 0.020 |
Why?
| Prospective Studies | 2 | 2014 | 6276 | 0.020 |
Why?
| Phosphorylation | 2 | 2005 | 1562 | 0.020 |
Why?
| Interleukin-2 | 1 | 2012 | 416 | 0.020 |
Why?
| Time Factors | 1 | 2000 | 6182 | 0.020 |
Why?
| Monophenol Monooxygenase | 1 | 2008 | 9 | 0.020 |
Why?
| Adolescent | 3 | 2012 | 17935 | 0.020 |
Why?
| Predictive Value of Tests | 1 | 2014 | 1813 | 0.020 |
Why?
| Immunoenzyme Techniques | 1 | 2009 | 193 | 0.020 |
Why?
| Radioimmunotherapy | 1 | 2008 | 10 | 0.020 |
Why?
| Interleukin-8 | 1 | 2009 | 241 | 0.020 |
Why?
| Genes, Insect | 2 | 1998 | 19 | 0.020 |
Why?
| Vaccines, DNA | 1 | 2008 | 30 | 0.020 |
Why?
| Vascular Endothelial Growth Factors | 1 | 2008 | 61 | 0.020 |
Why?
| Immunotoxins | 1 | 2008 | 33 | 0.020 |
Why?
| Immunization, Passive | 1 | 2008 | 79 | 0.020 |
Why?
| Wings, Animal | 2 | 1998 | 32 | 0.020 |
Why?
| Vaccines, Subunit | 1 | 2008 | 41 | 0.020 |
Why?
| S100 Calcium Binding Protein G | 1 | 2007 | 8 | 0.020 |
Why?
| Calbindin 2 | 1 | 2007 | 8 | 0.020 |
Why?
| Animals, Genetically Modified | 2 | 1998 | 216 | 0.020 |
Why?
| Down-Regulation | 1 | 2009 | 605 | 0.020 |
Why?
| Egg Proteins | 1 | 2007 | 19 | 0.020 |
Why?
| HLA-A2 Antigen | 1 | 2007 | 38 | 0.020 |
Why?
| Biomarkers, Tumor | 1 | 2013 | 1045 | 0.020 |
Why?
| HSP72 Heat-Shock Proteins | 1 | 2007 | 27 | 0.020 |
Why?
| Hot Temperature | 1 | 2008 | 303 | 0.020 |
Why?
| Ovalbumin | 1 | 2007 | 166 | 0.020 |
Why?
| Mutation | 3 | 2006 | 3371 | 0.020 |
Why?
| Tumor Necrosis Factor-alpha | 1 | 2012 | 1137 | 0.020 |
Why?
| Cytotoxicity, Immunologic | 1 | 2007 | 198 | 0.020 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2007 | 107 | 0.020 |
Why?
| Drug Synergism | 1 | 2007 | 316 | 0.020 |
Why?
| Transplantation, Isogeneic | 1 | 2006 | 17 | 0.020 |
Why?
| Antigen-Antibody Reactions | 1 | 2006 | 49 | 0.020 |
Why?
| Transplantation, Heterologous | 1 | 2006 | 188 | 0.020 |
Why?
| Bone Marrow Cells | 1 | 2007 | 272 | 0.020 |
Why?
| Dosage Forms | 1 | 2005 | 10 | 0.020 |
Why?
| Tocopherols | 1 | 2005 | 22 | 0.020 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2008 | 340 | 0.020 |
Why?
| Ki-67 Antigen | 1 | 2005 | 104 | 0.020 |
Why?
| alpha-Macroglobulins | 1 | 2005 | 24 | 0.020 |
Why?
| Ultrasonics | 1 | 2005 | 51 | 0.020 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 145 | 0.020 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 163 | 0.020 |
Why?
| T-Cell Antigen Receptor Specificity | 1 | 2004 | 41 | 0.020 |
Why?
| HeLa Cells | 1 | 2006 | 567 | 0.010 |
Why?
| Imatinib Mesylate | 1 | 2004 | 64 | 0.010 |
Why?
| Neovascularization, Pathologic | 1 | 2005 | 283 | 0.010 |
Why?
| Ependymoma | 1 | 2005 | 158 | 0.010 |
Why?
| Benzamides | 1 | 2004 | 169 | 0.010 |
Why?
| In Vitro Techniques | 1 | 2005 | 1044 | 0.010 |
Why?
| Cell-Free System | 1 | 2003 | 47 | 0.010 |
Why?
| CD40 Antigens | 1 | 2003 | 80 | 0.010 |
Why?
| Tomography, X-Ray Computed | 1 | 2012 | 2404 | 0.010 |
Why?
| Protein Folding | 1 | 2003 | 243 | 0.010 |
Why?
| Severity of Illness Index | 1 | 2009 | 2590 | 0.010 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2007 | 688 | 0.010 |
Why?
| Combined Modality Therapy | 1 | 2004 | 1127 | 0.010 |
Why?
| Cell Differentiation | 1 | 2007 | 1709 | 0.010 |
Why?
| Gene Expression Profiling | 1 | 2006 | 1550 | 0.010 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2006 | 1360 | 0.010 |
Why?
| Pupa | 1 | 1998 | 10 | 0.010 |
Why?
| Genes, Lethal | 1 | 1998 | 25 | 0.010 |
Why?
| Recombinant Fusion Proteins | 1 | 2001 | 617 | 0.010 |
Why?
| Crosses, Genetic | 1 | 1998 | 141 | 0.010 |
Why?
| Abdomen | 1 | 1998 | 105 | 0.010 |
Why?
| DNA, Complementary | 1 | 1998 | 262 | 0.010 |
Why?
| Larva | 1 | 1998 | 193 | 0.010 |
Why?
| Sequence Homology, Amino Acid | 1 | 1998 | 353 | 0.010 |
Why?
| Cytoplasm | 1 | 1998 | 255 | 0.010 |
Why?
| Muscles | 1 | 1998 | 328 | 0.010 |
Why?
| HIV Infections | 1 | 2010 | 2471 | 0.010 |
Why?
| Retina | 1 | 1998 | 269 | 0.010 |
Why?
| Base Sequence | 1 | 1998 | 2121 | 0.010 |
Why?
| Gene Expression Regulation, Developmental | 1 | 1998 | 796 | 0.010 |
Why?
| Risk Factors | 1 | 2006 | 8715 | 0.010 |
Why?
| Retrospective Studies | 1 | 2006 | 12615 | 0.010 |
Why?
|
|
Graner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|